SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) — Market Cap & Net Worth
Market Cap & Net Worth: SHANG.FOS.PHARM.GR.H YC 1 (08HH)
SHANG.FOS.PHARM.GR.H YC 1 (F:08HH) has a market capitalization of $1.30 Billion (€1.11 Billion) as of May 6, 2026. Listed on the F stock exchange, this Germany-based company holds position #8002 globally and #1060 in its home market, demonstrating a -6.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANG.FOS.PHARM.GR.H YC 1's stock price €2.01 by its total outstanding shares 551940500 (551.94 Million).
SHANG.FOS.PHARM.GR.H YC 1 Market Cap History: 2020 to 2026
SHANG.FOS.PHARM.GR.H YC 1's market capitalization history from 2020 to 2026. Data shows growth from $1.17 Billion to $1.30 Billion (310.60% CAGR).
SHANG.FOS.PHARM.GR.H YC 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANG.FOS.PHARM.GR.H YC 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 08HH by Market Capitalization
Companies near SHANG.FOS.PHARM.GR.H YC 1 in the global market cap rankings as of May 6, 2026.
Key companies related to SHANG.FOS.PHARM.GR.H YC 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #534 globally with a market cap of $49.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #573 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #534 | Zoetis Inc | NYSE:ZTS | $49.60 Billion | $112.54 |
| #573 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.24 |
SHANG.FOS.PHARM.GR.H YC 1 Historical Marketcap From 2020 to 2026
Between 2020 and today, SHANG.FOS.PHARM.GR.H YC 1's market cap moved from $1.17 Billion to $ 1.30 Billion, with a yearly change of 310.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.30 Billion | -4.20% |
| 2025 | €1.35 Billion | +22.93% |
| 2024 | €1.10 Billion | +11.55% |
| 2023 | €986.31 Million | -24.75% |
| 2022 | €1.31 Billion | +3.58% |
| 2021 | €1.27 Billion | +7.72% |
| 2020 | €1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of SHANG.FOS.PHARM.GR.H YC 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, le… Read more